AI-driven venomics, cryo-EM, and computational engineering accelerate venom-to-drug discovery

Animal venoms are a vast, underexplored reservoir of potent pharmacologically active molecules, yet their translation into clinical therapeutics has historically been slow. Traditional methods for identifying and characterizing these compounds are often laborious and inefficient, creating a significant bottleneck in drug discovery. This gap is particularly critical for addressing challenges like treatment resistance in diseases such as esophageal adenocarcinoma, where novel mechanisms of action are urgently needed. Overcoming these barriers requires innovative approaches to unlock the full therapeutic potential of venom-derived peptides.

This review synthesizes recent advancements across several high-impact technologies that are transforming venom-to-drug discovery. It specifically examines the contributions of AI-driven venomics, cryo-electron microscopy (cryo-EM), and computational peptide engineering in overcoming historical barriers. The authors analyze how these tools enhance the identification, characterization, and optimization of pharmacologically active molecules derived from animal venoms, aiming to accelerate their translation into clinical therapeutics. The review discusses the integration of these methodologies to create a more efficient and targeted drug discovery pipeline.

The review highlights that AI-driven venomics is revolutionizing the initial screening and target prediction phases, enabling rapid identification of novel bioactive peptides from complex venom mixtures. This includes machine learning approaches like Molecular Arms Race Classifier (MARC) for predicting ion channel targets (sodium, potassium, and calcium channels) of cysteine-rich venom peptides. > Cryo-EM provides unprecedented atomic-level structural insights into venom peptides and their interactions with target receptors, facilitating rational drug design and modification. Computational peptide engineering further optimizes these candidates for enhanced potency, selectivity, and stability, addressing issues like bioavailability and immunogenicity. These integrated approaches are significantly shortening the discovery timeline, moving beyond traditional bioassay-guided fractionation to a more targeted and efficient pipeline, thereby accelerating the translation of venom components into viable drug candidates.